COVID Clinical Trial
Official title:
Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy: an Italian Polispecialistic Society of Young Surgeons (S.P.I.G.C.) Survey
| Verified date | March 2022 |
| Source | Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The Coronavirus Emergency has severely affected Italian Healthcare National System. This event made it necessary to adopt extraordinary containment measures and to allocate extraordinary resources in Italian hospitals. In many centers routinely elective surgical activity has been decreased or even completely abolished. We believe that this exceptional condition is being consequently having a significant impact on surgical training programs.
| Status | Completed |
| Enrollment | 800 |
| Est. completion date | May 1, 2020 |
| Est. primary completion date | April 15, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Residents in the following surgical specialities: cardiothoracic surgery, colon and rectal surgery, general surgery, gynecology and obstetrics, gynecologic oncology, neurological surgery, ophthalmic surgery, oral and maxillofacial surgery, orthopaedic surgery, otorhinolaryngology, pediatric surgery, plastic and maxillofacial surgery, urology, and vascular surgery Exclusion Criteria: - Undergratuated and postgraduated students - Consultants in surgical areas |
| Country | Name | City | State |
|---|---|---|---|
| Italy | U.O.C. Chirurgia Generale Universitaria "V. Bonomo" | Bari | |
| Italy | Ospedale Perrino Asl Brindisi | Brindisi | |
| Italy | Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro | Catanzaro | |
| Italy | Ospedale Policlinico San Martino | Genova | |
| Italy | Azienda Ospedaliera San Camillo-Forlanini | Roma | |
| Italy | IRCCS Fondazione Policlinico Universitario Agostino Gemelli | Roma | |
| Italy | Ospedale Cristo re | Roma |
| Lead Sponsor | Collaborator |
|---|---|
| Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia |
Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measure of the impact of first wave of COVID Pandemic on surgical specialist training programs | Analysis of this outcome with regard to the different surgical subspecialities and different Italian medical centers | 1-3 months after the beginning of COVID emergency in Italy | |
| Primary | Measure of the impact of second wave of COVID Pandemic on surgical specialist training programs | Analysis of this outcome with regard to the different surgical subspecialities and different Italian medical centers | 1 year after the beginning of COVID emergency in Italy | |
| Primary | Measure of the impact of third wave of COVID Pandemic on surgical specialist training programs | Analysis of this outcome with regard to the different surgical subspecialities and different Italian medical centers | 2 years after the beginning of COVID emergency in Italy | |
| Secondary | Measure of impact of first wave of COVID Pandemic on wellness of residents | Analysis of this outcome with regard to the different surgical subspecialities and different Italian medical centers | 1-3 months after the beginning of COVID emergency in Italy | |
| Secondary | Measure of impact of second wave of COVID Pandemic on wellness of residents | Analysis of this outcome with regard to the different surgical subspecialities and different Italian medical centers | 1 year after the beginning of COVID emergency in Italy | |
| Secondary | Measure of impact of third wave of COVID Pandemic on wellness of residents | Analysis of this outcome with regard to the different surgical subspecialities and different Italian medical centers | 2 years after the beginning of COVID emergency in Italy |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
| Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
| Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
| Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
| Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
| Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
| Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
| Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
| Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
| Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
| Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
| Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
| Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
| Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
| Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
| Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |